undamentalytics Newsletter
Sign in

Altimmune, Inc. balance sheet

At the end of fiscal 2025, Altimmune, Inc. had total assets of $280m, total liabilities of $55.0m and shareholders' equity of $225m. It held $43.8m in cash against $35.0m of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents1211393491161901111353744
Receivables55——————0111
Total current assets24204233939230204193210137278
Goodwill2219—00——————
Total assets272338635554245219207211139280
Accounts payable312000125203
Deferred revenue (current)——00000—————
Total current liabilities655454121817121015
Long-term debt0—1122215——34
Total debt0—15222154035
Total liabilities15761469192022171655
Shareholders' equity121632394846226199185194124225
Non-controlling interests and other (assets − liabilities − equity)———9————————
Shares outstanding———————41m49m—72m—

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ALT vs LYELAIM vs ALTALT vs IBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Altimmune, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Altimmune, Inc.